FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Responses	s)															
Name and Address of Reporting Person * Felix Lourdes					2. Issuer Name and Ticker or Trading Symbol BioCorRx Inc. [BICX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner						
(Last) (First) (Middle) 2390 EAST ORANGEWOOD AVENUE, SUITE 500					3. Date of Earliest Transaction (Month/Day/Year) 09/30-05:00/2020						X Officer (give title below) Other (specify below) President and CFO						
ANAHEI	IM, CA 92	(Street)		4. If	Amendment	Date	Origin	al File	ed(Month	/Day/Year)		_X_ Form fil	ed by One Repo	Group Filing orting Person one Reporting	_	plicable	Line)
(City		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	Exec any			(Instr. 8)		4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Beneficia Reported	nt of Securities ally Owned Following Transaction(s)		Form:	ship of B	7. Nature of Indirect Beneficial	
				(Mo	(Month/Day/Year)		Code	V	Amoun	(A) or (D)	Price	(Instr. 3 and 4)			or India (I) (Instr. 4	Indirect (Instr. 4	
Common \$0.001	Stock, par	r value	09/30- 05:00/2020			A	\ <u>(1)</u>	2	2,631	A	\$ 0	37,855			D		
					ative Securit		t	the fo	rm dis	splays a of, or Ben	curre eficial	ntly valid	OMB con	spond unle trol numbe			
1. Title of	2	3. Transaction			outs, calls, w	arran 5.					T	itle and	8. Price of	9. Number	of 10.		11. Natur
Derivative Security	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Y	Execution Da	ate, if	te, if Transaction Code		ber	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amo Und Secu	ount of lerlying arities tr. 3 and	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ow For Der Sec Dire or I	nership m of ivative urity: ect (D) ndirect tr. 4)	nip of Indirect Beneficia Ownershi (Instr. 4)	
					Code V	(A)		Date Exerci		Expiration Date	n Title	Amount or Number of Shares					
Repor	ting O	wners															

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Felix Lourdes 2390 EAST ORANGEWOOD AVENUE SUITE 500 ANAHEIM, CA 92806	X		President and CFO				

Signatures

/s/ Lourdes Felix	10/13-05:00/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to \$5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was \$1.90.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.